Trial Profile
A Randomized, Open-Label, Study to Evaluate the Immunogenicity of One Dose of Live Attenuated Influenza Vaccine (LAIV) Compared to One Dose of Trivalent Inactivated Influenza Vaccine (IIV) in Adults 18-49 Years of Age
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine live (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics
- 10 Apr 2017 New trial record